At present, blocking B7 ligand inhibitory interactions to improve T-cell infiltration is routinely used as a strategy to guide tumor immunotherapy, especially PD-1 and CTLA-4 blocking antibodies in renal cancer and melanoma [6]. Here, CTLA4 is linked to neoplasm.